Parkinson’s Progression Markers Initiative (PPMI): A Biomarker Engine for Therapeutic Development for PD and Related Synucleinopathies
Objective: PPMI is a longitudinal, observational study investigating clinical, imaging, genetic and biofluid biomarkers to accelerate therapeutic development for Parkinson’s disease (PD) and related synucleinopathies…Contribution of β-band functional connectivity to the α-synuclein propagation in early-stage Parkinson’s Disease: insights from the analysis of brain network properties
Objective: To investigate the relationship between CSF α-synuclein levels and EEG-based network properties, aiming to clarify their role in PD pathophysiology. Background: Parkinson’s disease (PD)…Assessment of the impact of the diabetic features hyperglycemia and insulin resistance on fibril induced synucleinopathy
Objective: Investigate the effects of diabetic features on the induction and severity of synucleinopathies such as Parkinson’s disease (PD). Background: Type 2 diabetes (T2D) is…Disease Modifying Potential of a Novel ROCK Inhibitor in Rodent Models of Synucleinopathy
Objective: Evaluate the impact of a novel Rho-associated kinase (ROCK) inhibitor on alpha-synuclein (a-syn) pathology, neuroinflammation, and dopamine neurodegeneration in the AAV-a-syn overexpression and a-syn…Sleep-wake Alterations are Associated with a Decreased DTI-ALPS, a Marker of Perivascular Glymphatic Functioning, in Patients with Isolated REM Sleep Behavior Disorder
Objective: We aimed to explore circadian disruption in iRBD and its association with the Diffusion Tensor Imaging- ALong the Perivascular Space (DTI-ALPS) index, a proxy…Epigenome-wide and gene-targeted epigenetic profile of isolated REM Sleep Behaviour Disorder: a clinico-molecular study
Objective: Comprehensively characterize the epigenetic profile of isolated REM Sleep Behaviour Disorder (iRBD) using genome-wide and gene-targeted approaches, linking it to clinical measures and phenoconversion.…Paradoxical Association of Kinetics of α-Synuclein Seed Amplification 24-hrs Assay and Clinico-Pathological Markers of Parkinson’s disease
Objective: To investigate the association between baseline α-synuclein seed amplification assay (SAA) parameters and clinical and biomarker features of Parkinson’s disease (PD) at baseline and…Real world application of alpha-synuclein skin biopsy in the diagnosis of synucleinopathies at a tertiary care center
Objective: The goal of this study is to review the real-world application of alpha-synuclein skin biopsy at a tertiary care center. Background: Synucleniopathies including Parkinson’s…Validation of CSF Alpha-synuclein SAA in an Autopsy Cohort with Systemic Assessment of Lewy Pathology Including the Body
Objective: Based on the recent recommendations by international neuropathologists [1], we attempted to evaluate the diagnostic accuracy of cerebrospinal fluid (CSF) alpha-synuclein (α-syn) seeding amplification…Dopaminometer: A Smartphone-Based Application to Predict Striatal Dopaminergic Deficit in Prodromal and Manifest Parkinson’s disease
Objective: To assess the feasibility of a smartphone-based application (“Dopaminometer”) for predicting abnormal vs. normal dopamine transporter (DaT) scans and dopaminergic ratios in individuals with…
- 1
- 2
- 3
- …
- 17
- Next Page »